Form 4: C4 Therapeutics Chief Legal Officer Reports Stock Transactions
SEC Form 4 Filing
Jolie Siegel, Chief Legal Officer of C4 Therapeutics, reports the vesting and tax withholding of performance restricted stock units.
Summary
- On September 16, 2024, Jolie Siegel, the Chief Legal Officer of C4 Therapeutics, engaged in transactions involving the company's common stock.
- Siegel acquired 2,250 shares of common stock through the vesting of performance restricted stock units (PRSUs).
- 661 shares were withheld by C4 Therapeutics to satisfy tax obligations related to the vesting of the PRSUs.
- Following these transactions, Siegel directly owns 53,840 shares of C4 Therapeutics common stock and 14,250 performance restricted stock units.
- The price per share for the tax withholding was $6.36.
Sentiment
Score: 5
Explanation: The document is a standard SEC filing detailing stock transactions, with no inherent positive or negative sentiment. It's a neutral disclosure of information.
Industry Context
This filing is a routine disclosure of stock transactions by a company insider, as required by SEC regulations. It provides transparency into the trading activities of key personnel and their holdings in the company.
Stakeholder Impact
- The transactions may have a minor impact on shareholders due to the change in ownership, but the effect is likely negligible given the relatively small number of shares involved.
Key Dates
| Date | Description |
|---|---|
| 09/16/2024 | Date of stock transactions (vesting of PRSUs and tax withholding). |
| 09/17/2024 | Date of signature for the report. |
| 02/28/2025 | Expiration date of the Performance Restricted Stock Units. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.